Key result
cBIN1 gene therapy restores LV electrical and mechanical synchrony in preclinical ischemic heart failure.
Why the study?
Heart failure is associated with disruption of transverse tubule organization and calcium-handling microdomains, and whether cBIN1 gene therapy restores left ventricular electrical and mechanical synchrony in ischemic heart failure remained to be evaluated.
Does cBIN1 gene therapy restore left ventricular (LV) electrical and mechanical synchrony in a large-animal model of ischemic HF?
Does cBIN1 gene therapy restore left ventricular (LV) electrical and mechanical synchrony in a large-animal model of ischemic HF?
Answers are grounded in this paper and cite their sources.
cBIN1 gene therapy is being evaluated for its potential to restore ventricular synchrony and structural remodeling in a preclinical model of ischemic heart failure.
Heart failure (HF) is associated with disruption of transverse tubule (t-tubule) organization and calcium-handling microdomains, which is closely linked to impaired excitation–contraction coupling. Cardiac bridging integrator 1 (cBIN1), a membrane scaffolding protein essential for t-tubule organization, is markedly downregulated in HF,1 and cBIN1 gene therapy has been shown to improve systolic function.2 We evaluated whether cBIN1 gene therapy restores left ventricular (LV) electrical and mechanical synchrony in a large-animal model of ischemic HF and examined associated structural remodeling.
No takes yet. Share an insight, caveat, or question.
Yazaki et al. (2026) studied Ischemic Heart Failure. cBIN1 gene therapy was evaluated on Left ventricular (LV) electrical and mechanical synchrony and associated structural remodeling. cBIN1 gene therapy restores ventricular synchrony in a pre-clinical large-animal model of ischemic heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: